Inactive Instrument

Atreca, Inc. Stock OTC Markets




Biotechnology & Medical Research

Delayed OTC Markets 15:28:38 2024-06-14 EDT 5-day change 1st Jan Change
0.09 USD -1.32% Intraday chart for Atreca, Inc. 0.00% -31.82%
Sales 2023 * - Sales 2024 * - Capitalization 1.86M 2.54M
Net income 2023 * -64M -87.37M Net income 2024 * -38M -51.87M EV / Sales 2023 * -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
P/E ratio 2024 *
Employees 90
Yield 2023 *
Yield 2024 *
Free-Float 83.01%
More Fundamentals * Assessed data
Dynamic Chart
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
More about the company